DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

Eli Lilly & Co. (NYSE: LLY)



company name or ticker
Company Photos
(Click to zoom)

Eli Lilly to drop development of lupus drug

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

How Will Eli Lilly (LLY) Stock Be Affected by This Coverage Initiation?

Overpriced Expectations: Alcobra Will Get To Second Base, But No Home Run. Options Are Mispriced For

Overpriced Expectations: Alcobra Will Get To Second Base, But No Home Run. Options Are Mispriced For An Unlikely Event

Pharma Stocks: Surprising Shift In U.S. Drug Market

2 Reasons Why Eli Lilly's New Diabetes Drug Might Not Become A Blockbuster

AstraZeneca Posts Positive Data on its Type II Diabetes Drug - Analyst Blog

Boehringer aims to cut up to 600 jobs in Germany

3 Reasons Eli Lilly & Co.'s Stock Could Fall

Management at Eli Lilly & Co. has faced a mountain of challenges in the wake of debilitating patent losses, but the stock has held strong regardless. Here are three reasons that rally may not continue into the future.

Eli Lilly: A Full Suite Of Offerings For Diabetic Patients

See More Articles...